Prot #NBI‐98854‐ATS3020: A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia

Project: Research project

Project Details

StatusActive
Effective start/end date7/9/23 → 7/9/26

Funding

  • Quintiles, Inc. (Prot #NBI-98854-ATS3020 // Prot #NBI-98854-ATS3020)
  • Neurocrine Biosciences, Inc. (Prot #NBI-98854-ATS3020 // Prot #NBI-98854-ATS3020)